AlphAIalphai — Financial news for AI agents
simplywall.stAUG 272 min read$SMMT

Summit Therapeutics (SMMT) Is Up 8.5% After Ivonescimab’s Phase III Biliary Cancer Survival Win

Summit Therapeutics (SMMT) rose 8.5% after partner Akeso's Phase III trial showed ivonescimab plus chemotherapy improved survival rates in advanced biliary tract cancer. The drug's success adds to its lung cancer data and ongoing FDA review. Summit projects $897.3M revenue and $169.7M earnings by 2029, with analysts estimating potential $2.5B revenue by 2029.

Original reporting
simplywall.st
Published Aug 27, 2026, 9:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 12:11 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefTechnology
Primary signal
$SMMT
Bullish
high confidence
Mentioned
$SMMT
Relevance
8/10
alphai data visualization · based on simplywall.st
Decision brief

The 30-second read

$SMMTBullishHigh
01

Why it matters

The data could materially improve the company's valuation and accelerate regulatory milestones, but execution risk remains.

02

Market read

First‑report trial data for a late‑stage oncology candidate, likely to move the stock and influence sector sentiment.

03

What to watch

Regulatory risk remains high; data from other ongoing trials may temper enthusiasm.

Relevance 8/10Novelty 9/10Timing: today

Background

Summit Therapeutics (SMMT) announced a Phase III trial win for ivonescimab in biliary tract cancer in China, adding to prior lung cancer data and ongoing US FDA review.

Company-level read

Ticker impact

$SMMTBullishHigh confidence
Context

Phase III HARMONi-GI1 trial in China showed ivonescimab plus chemotherapy improved overall survival, progression‑free survival and response rate versus durvalumab.

Expected impact

Potential upside of 10‑15% in the next 1‑2 weeks as investors price in broader indication potential.

Evidence & confidence

Phase III survival benefit is a material catalyst for a biotech with pending US FDA decision; market typically reacts strongly to such data.

Market effects

Sector

Strengthens the bispecific antibody segment and may boost peer biotech valuations.

Regional

Positive for China‑based oncology trial sites and partner Akeso.

Global

Adds confidence to US investors in late‑stage oncology pipelines.

Counterpoint

What could challenge this read

If overall survival benefit does not meet FDA expectations, the rally could be short‑lived.

Key entities

  • company
    Summit Therapeutics

    Biotech developer of ivonescimab.

  • partner
    Akeso

    Conducted the Chinese Phase III trial.

Read at source← All news

Also covered by

3 outlets

Related articles

AUG 27
$SMMTHighAI 9/10

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Summit Therapeutics (SMMT) shares rose 6.5% after partner Akeso reported positive phase III study results for ivonescimab in biliary tract cancer, showing superiority over AstraZeneca's (AZN) Imfinzi. The study met primary and secondary endpoints, including overall survival. Summit holds exclusive licensing rights for ivonescimab in multiple regions, excluding China. Year-to-date, SMMT shares are down 18.6% against industry growth of 3.2%.

finance.yahoo.com2 min
AUG 26
$SMMTHighAI 8/10

Summit Therapeutics Stock Rises 8%

Summit Therapeutics (SMMT) shares rose 7.78% to $14.40 Wednesday, possibly due to partner Akeso's positive Phase III trial results for ivonescimab in advanced biliary tract cancer. The stock traded between $14.11 and $15.10, with volume at 7.52 million shares. Akeso reported statistically significant overall survival benefits in the HARMONi-GI1 study.

rttnews.com1 min
AUG 26
$SMMTHighAI 9/10

Summit Therapeutics Shares Surge on Positive Phase III Data From Chinese Partner Akeso

Summit Therapeutics (SMMT) shares rose 8% to $14.40 after partner Akeso reported positive Phase III trial results for ivonescimab in advanced biliary tract cancer, meeting primary and secondary endpoints. The drug, a bispecific antibody, is key to Summit's pipeline, with an FDA decision pending for NSCLC. Investors consider potential and risks, including cash burn and recent stock offering.

asktraders.com2 min
AUG 26
$SMMTHighAI 9/10

Why is Summit Therapeutics stock surging today?

Summit Therapeutics (SMMT) stock rose 8.5% in pre-market trading after positive clinical trial data for its drug ivonescimab. Partner Akeso reported success in a Phase III study for advanced biliary tract cancer, and Summit published results showing reduced disease progression risk in lung cancer. Analysts Guggenheim and Bernstein SocGen updated their ratings and price targets. The rally was company-specific, with the broader market showing little movement.

investing.com2 min
AUG 26
$SMMTHighAI 9/10

Summit Therapeutics stock jumps on partner’s cancer trial data

Summit Therapeutics (SMMT) shares rose 7.75% after its partner Akeso's Phase III cancer study met primary and key secondary endpoints. The study showed ivonescimab plus chemotherapy improved overall survival in advanced biliary tract cancer. Analysts had mixed reactions, with H.C. Wainwright maintaining a Neutral rating and Guggenheim reiterating a Buy with a $38 price target.

investing.com2 min